These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 35847239)

  • 1. Long-term observation of antibody titers against SARS-CoV-2 following vaccination.
    Sugiyama K; Suzuki C; Aoyama M; Toyota N; Nakagawa N; Shozu M; Nakai K; Iwano K
    Public Health Pract (Oxf); 2022 Dec; 4():100297. PubMed ID: 35847239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Mittal A; Solera JT; Ferreira VH; Kothari S; Kimura M; Pasic I; Mattsson JI; Humar A; Kulasingam V; Ierullo M; Kumar D; Hosseini-Moghaddam SM
    Transplant Cell Ther; 2023 Nov; 29(11):706.e1-706.e7. PubMed ID: 37582470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiency.
    Nielsen BU; Drabe CH; Barnkob MB; Johansen IS; Hansen AKK; Nilsson AC; Rasmussen LD
    Front Immunol; 2022; 13():934476. PubMed ID: 35967433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Antibody Titers after SARS-CoV-2 Vaccination-Insights from Self-Paid Tests at a General Internal Medicine Clinic.
    Kusunoki H; Ekawa K; Ekawa M; Kato N; Yamasaki K; Motone M; Shimizu H
    Medicines (Basel); 2023 Apr; 10(4):. PubMed ID: 37103782
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study.
    Tillmann FP; Figiel L; Ricken J; Still H; Korte C; Plaßmann G; Harth A; Jörres A; von Landenberg P
    J Clin Med; 2022 Jun; 11(11):. PubMed ID: 35683580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan.
    Sakamoto A; Yoshimura M; Itoh R; Ozuru R; Ishii K; Sechi Y; Nabeshima S; Hiromatsu K
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic.
    Brehm TT; Thompson M; Ullrich F; Schwinge D; Addo MM; Spier A; Knobloch JK; Aepfelbacher M; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J
    Int J Hyg Environ Health; 2021 Sep; 238():113851. PubMed ID: 34601375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk factors of SARS-CoV-2 antibody level differences in healthcare workers post vaccination in Siloam hospitals: A nationwide multicenter study.
    Widysanto A; Prasetya IB; Meriyanti T; Sungono V; Setiawan DL; Gunawan E; Adiputra B; Lorens JO; Santi T; Pradhana CML; Yusuf I; Gunawan C
    Infect Med (Beijing); 2022 Dec; 1(4):229-235. PubMed ID: 38013914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insufficient anti-spike RBD IgA responses after triple vaccination with intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2.
    Yoshimura M; Sakamoto A; Ozuru R; Kurihara Y; Itoh R; Ishii K; Shimizu A; Chou B; Sechi Y; Fujikane A; Nabeshima S; Hiromatsu K
    Heliyon; 2024 Jan; 10(1):e23595. PubMed ID: 38187240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays.
    Padoan A; Cosma C; Bonfante F; Della Rocca F; Barbaro F; Santarossa C; Dall'Olmo L; Pagliari M; Bortolami A; Cattelan A; Cianci V; Basso D; Plebani M
    Clin Chem Lab Med; 2022 Feb; 60(3):456-463. PubMed ID: 34911170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination strategy and anti - SARS-CoV-2 S titers in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
    Cavalcanti E; Isgrò MA; Rea D; Di Capua L; Trillò G; Russo L; Botti G; Miscio L; Buonaguro FM; Bianchi AAM
    Infect Agent Cancer; 2021 May; 16(1):32. PubMed ID: 33980271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
    Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
    ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers.
    Kwon SR; Kim N; Park H; Minn D; Park S; Roh EY; Yoon JH; Shin S
    J Korean Med Sci; 2022 May; 37(19):e135. PubMed ID: 35578582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
    Özgür D; Tütüncü EE
    Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial SARS-CoV-2 antibody titers in vaccinated dialysis patients: prevalence of unrecognized infection and duration of seroresponse.
    Hsu CM; Weiner DE; Manley HJ; Miskulin D; Ladik V; Frament J; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    medRxiv; 2023 Mar; ():. PubMed ID: 36993760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Dynamic Humoral Response to SARS-CoV-2 mRNA Vaccines in Patients on Peritoneal Dialysis.
    Quiroga B; Soler MJ; Ortiz A; Gansevoort RT; Leyva A; Rojas J; de Sequera P;
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination.
    Guiomar R; Santos AJ; Melo AM; Costa I; Matos R; Rodrigues AP; Kislaya I; Silva AS; Roque C; Nunes C; Aguiar J; Graça F; Silva Graça A; Machado A
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination.
    Lee N; Jeong S; Lee SK; Cho EJ; Hyun J; Park MJ; Song W; Kim HS
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Third Dose of an Inactivated Vaccine Dramatically Increased the Levels and Decay Times of Anti-SARS-CoV-2 Antibodies, but Disappointingly Declined Again: A Prospective, Longitudinal, Cohort Study at 18 Serial Time Points Over 368 Days.
    Liang XM; Xu QY; Jia ZJ; Wu MJ; Liu YY; Lin LR; Liu LL; Yang TC
    Front Immunol; 2022; 13():876037. PubMed ID: 35572536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durability of Immune Response after Application of a Third Dose of SARS-CoV-2 Vaccination in Liver Transplant Recipients.
    Passenberg M; Authorsen-Grudmann R; Frey A; Korth J; Zmudzinski J; Anastasiou OE; Möhlendick B; Schmidt H; Rashidi-Alavijeh J; Willuweit K
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.